News
MYCOF
0.470
+13.23%
0.055
Mydecine announces debt settlements
Seeking Alpha · 03/06 12:49
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
Benzinga · 01/03 14:33
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Benzinga · 12/20/2022 01:23
Psychedelic Company Sale: Mydecine Gets Over $2.5M For Wholly-Owned Tech Subsidiary Business
Benzinga · 12/13/2022 18:47
MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT
Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular empha...
CNW Group · 11/29/2022 01:38
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Benzinga · 11/22/2022 00:13
Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
DENVER, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly addres...
GlobeNewswire · 11/21/2022 17:01
Mydecine's Q3 Financials & Update, Sustained Target On Smoking Cessation For Next 12 Months
Benzinga · 11/15/2022 17:25
Mydecine Innovations Group GAAP EPS of -$0.35
Seekingalpha · 11/15/2022 11:23
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES NEW CFO
Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular empha...
CNW Group · 09/23/2022 15:35
World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business landscape.
Benzinga · 08/30/2022 23:01
BRIEF-Mydecine Innovations Group Announces Common Share Subscription Agreement
BRIEF-Mydecine Innovations Group Announces Common Share Subscription Agreement
Reuters · 08/29/2022 20:08
Mydecine Innovations enters into $245M share subscription agreement, CFO resigns
Biotechnology company Mydecine Innovations Group (OTCPK:MYCOF) said it has entered into a ...
Seekingalpha · 08/19/2022 19:31
Mydecine Innovations Group Announces Private Placement Of 326,666 Shares At $0.75/Share
https://www.globenewswire.com/news-release/2022/08/19/2501703/0/en/Mydecine-Innovations-Group-Announces-Private-Placement-Interim-Changes-to-Management-and-Board-of-Directors.html
Benzinga · 08/19/2022 17:51
IIROC Trade Resumption - MYCO
Trading resumes in:
CNW Group · 08/19/2022 16:09
Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors
DENVER, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly addre...
GlobeNewswire · 08/19/2022 15:06
Mydecine Innovations Group Reports Q2 Financial Results And Management Updates
After the resignation of several key board members on August 12, Mydecine Innovations Group (OTC: MYCOF) reported its financial results. For the period corresponding to the six months ended June 30, 2022: Total cash was $324,146
Benzinga · 08/16/2022 20:26
Mydecine Innovations Group GAAP EPS of -C$0.35
Mydecine Innovations Group press release (<a href="https://seeki...
Seekingalpha · 08/16/2022 09:48
Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2022
DENVER, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported fina...
GlobeNewswire · 08/16/2022 01:46
MYDECINE INNOVATIONS GROUP ANNOUNCES RESIGNATION OF DIRECTORS
Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emph...
CNW Group · 08/12/2022 18:05
More
Webull provides a variety of real-time MYCOF stock news. You can receive the latest news about Mydecine Innovations Group Inc through multiple platforms. This information may help you make smarter investment decisions.
About MYCOF
Mydecine Innovations Group Inc. is a Canada-based biopharma and life sciences company. The Company is focused on the research, development and acceptance of alternative nature-sourced medicine. Its portfolio of companies includes Mydecine Health Sciences (MHS), Mindleap Health Inc. (Mindleap) and NeuroPharm, Inc (NPI). MHS is focused on developing fungtional mushroom products and psychedelic medicines for the consumer and professional healthcare market. NPI is a veterans-focused healthcare company that is developing pharmaceutical and natural health products for mental wellness in vulnerable populations, including veterans, emergency medical services (EMS) personnel and other high-risk constituencies. NPI is developing psilocybin-assisted psychotherapy to treat chronic post-traumatic stress disorder (PTSD). Mindleap offers a digital health platform that enables people connect with mental health specialists, who can help them to develop habits for a healthy mind.